The overall objective of this activity is to address the epidemiology, risk factors and key challenges in the evaluation and management of cardiovascular disease risk factors in liver transplant recipients. In particular, we will discuss practical approaches and pharmacologic considerations in the prevention and management of hypertension, dyslipidemia and diabetes in liver transplant recipients.
Yogish Kudva, MBBS
Yogish Kudva is an adult endocrinologist focused on clinical research involving patients with type 1 diabetes. He has been involved in randomized trials of T1D since 2000, insulin pump trials since 2006 and artificial pancreas since 2009.
His clinical and research work includes beta cell transplantation for diabetes. His work is been funded by the NIH, JDRF, and The Helmsley Trust.
Lisa VanWagner, MD, MSc
Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois. She is board certified in transplant hepatology. Her laboratory utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease.
Her research group developed the first simple scoring model (CAR-OLT score) — accessible via web or smartphone apps — which enables health care providers, caregivers and patients to estimate 1-year risk for cardiovascular complications after liver transplantation.
Manhal (Manny) Izzy, MD
Dr. Manhal Izzy is a transplant hepatologist and an assistant professor at Vanderbilt University School of Medicine. He is a member of the educational committee of the International Liver Transplantation Society (ILTS). His research focuses on cardiovascular outcomes in patients with liver disease.